- Home
- CLRO vs NRSN Comparison
CLRO vs NRSN Comparison
Compare CLRO & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLRO | NRSN |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 14.2M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLRO | NRSN |
|---|---|---|
| Price | $5.03 | $0.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 1.6M | 249.7K |
| Earning Date | 05-18-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.59 | N/A |
| 52 Week Low | $2.71 | $0.25 |
| 52 Week High | $16.50 | $1.30 |
Technical Indicators
Market Signals| Indicator | CLRO | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 46.88 |
| Support Level | $4.44 | $0.39 |
| Resistance Level | $5.40 | $0.74 |
| Average True Range (ATR) | 0.42 | 0.06 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 17.40 | 75.65 |
Price Performance
Historical ComparisonAbout CLRO ClearOne Inc. (DE)
ClearOne Inc is currently engaged in activities that consist solely of fulfilling warranty and technical support obligations on legacy products, evaluating potential Strategic Transactions, managing and liquidating remaining assets of the company's legacy operating business, collecting accounts receivable and recovering prepaid assets, satisfying outstanding liabilities, and maintaining public-company compliance.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.